Safety and efficacy analysis of pembrolizumab dosing patterns in patients with advanced melanoma and non-small cell lung cancer

Abstract

Aim

To evaluate the impact of discrepancy between prescribed and recommended fixed 200 mg dose (P-F discrepancy) on immune-related adverse events (irAEs) and treatment efficacy in patients with advanced melanoma and NSCLC.

Methods

This retrospective study included 177 patients with advanced melanoma or non-small cell lung cancer (NSCLC) who received at least one cycle of single-agent pembrolizumab. We defined P-F discrepancy as the differences between prescribed pembrolizumab dose and 200 mg recommended dose, expressed in percentages. Our primary outcome was immune-related adverse events (irAEs), and our secondary outcomes included overall survival (OS) and progression free survival (PFS).

Results

The median P-F discrepancy was –21.5%, with the 25th and 75th percentile at –32% and –5.0% respectively. ROC curve analyses did not show any optimal cutoffs to prognosticate irAEs (AUC = 0.558 for all patients) or cancer mortality (AUC = 0.583 for melanoma; AUC = 0.539 for NSCLC) in either cancer type. Separate multivariable Cox analyses suggested no statistically significant association between P-F discrepancy and overall survival in patients with melanoma (HR 1.012, 95%CI 0.987–1.038, P = 0.362) or NSCLC (HR 0.998, 95%CI 0.978–1.019, P = 0.876).

Conclusion

There was no optimal pembrolizumab cut-off point to predict irAEs or treatment efficacy. We supported the use of weight-based pembrolizumab dosing, given the potential cost-saving and no differences in terms of irAEs or treatment efficacy in patients with advanced melanoma or NSCLC. Future studies on province- or national-level would be important to validate our findings.

Keywords

Pembrolizumab dose discrepancy toxicity treatment efficacy

Get full access to this article

View all access options for this article.

References

Patnaik

Kang

Rasco

, et al. Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res 2015; 21: 4286–4293.

U.S. National Library of Medicine. Study of pembrolizumab (MK-3475) in participants with progressive locally advanced or metastatic carcinoma, melanoma, or non-small cell lung carcinoma (P07990/MK-3475-001/KEYNOTE-001)(KEYNOTE-001). ClinicalTrials.gov Identifier: NCT01295827, 2011. Available at: https://clinicaltrials.gov/ct2/show/NCT01295827 (accessed 4 August 2020).

Hamid

Robert

Daud

, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol 2019; 30: 582–588.

Garon

Hellmann

Rizvi

, et al. Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study. J Clin Oncol 2019; 37: 2518–2527.

Reck

Rodriguez-Abreu

Robinson

, et al. Pembrolizumab versus chemotherapy for PD-L1 positive non-small-cell lung cancer. N Engl J Med 2016; 375: 1823–1833.

Bellmunt

de Wit

Vaughn

, KEYNOTE-045 Investigatorset al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 2017; 376: 1015–1026.

Powell

Liu

Sukari

, et al. KEYNOTE-055: a phase II trial of single agent pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who have failed platinum and cetuximab. J Clin Oncol 2015; 33: TPS3094–TPS3094.

Kim

Cutsem

, et al. Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. J Clin Oncol 2020; 38: 11–19.

Ahamadi

Freshwater

Prohn

, et al. Model-based characterization of the pharmacokinetics of pembrolizumab: a humanized anti-PD-1 monoclonal antibody in advanced solid tumors. CPT Pharmacometrics Syst Pharmacol 2017; 6: 49–57.

10.

Cancer Care Ontario. Drug formulary: pembrolizumab. Available at: https://www.cancercareontario.ca/en/drugformulary/drugs/monograph/44411 (accessed 4 August 2020).

11.

Common Terminology Criteria for Adverse Events (CTCAE). Protocol Development. CTEP. Available at: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm (accessed 4 August 2020).

12.

Eisenhauer

Therasse

Bogaerts

, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228–247.

13.

Freshwater

Kondic

Ahamad

, et al. Evaluation of dosing strategy for pembrolizumab for oncology indications. J Immunother Cancer 2017; 5: 43.

14.

Jang

Nakashima

, et al. A real-world data approach to determine the optimal dosing strategy for pembrolizumab. J Oncol Pharm Pract 2020; 0: 1–9.

15.

Hall

Zhang

Kim

, et al. Economics of alternative dosing strategies for pembrolizumab and nivolumab at a single academic cancer center. Cancer Med 2020; 9: 2106–2112.

16.

Cancer Care Ontario Beyond-Use Date Recommendations Report. Cancer Care Ontario. 2018. Available at: https://www.cancercareontario.ca/en/content/cancer-care-ontario-beyond-use-date-recommendations-report (accessed 10 November 2020).

17.

McMichael

Jefferson

Carey

, et al. Utility of the PhaSeal closed system drug transfer device. Am J Pharm Benefits 2011; 3: 9–16.

18.

Carey

Forrey

Haughs

, et al. Second look at utilization of a closed-system transfer device (PhaSeal). Am J Pharm Benefits 2011; 3: 311–318.

19.

Edwards

Solimando

, et al. Determination of extended sterility for single-use vials using the PhaSeal closed-system transfer device. J Hematol Oncol Pharm 2016; 6: 46–50.

20.

Arbour

Mezquita

Long

, et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol 2018; 36: 2872–2878.

21.

Scott

Pennell

NA.

Early use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab. J Thorac Oncol 2018; 13: 1771–1775.

22.

Ricciuti

Dahlberg

Adeni

, et al. Receiving baseline corticosteroids for palliative versus nonpalliative indication. J Clin Oncol 2019; 37: 1927–1934.

23.

Drakaki

Luhn

Wakelee

, et al. Association of systemic corticosteroids with overall survival in patients receiving cancer immunotherapy for advanced melanoma, non-small cell lung cancer or urothelial cancer in routine clinical practice. Ann Oncol 2019; 30: xi16–xi32.

24.

Pennell

Galligan

Fish

ED.

Sex affects immunity. J Autoimmun 2012; 38: J282–J291.

25.

Ghazeeri

Abdullah

Abbas

Immunological differences in women compared with men: overview and contributing factors. Am J Reprod Immunol 2011; 66: 163–169.

26.

Karpuzoglu

Zouali

The multi-faceted of estrogen on lymphocytes towards novel immune-interventions strategies for autoimmunity management. Clin Rev Allergy Immunol 2011; 40: 16–26.